Initial report of the use of an injectable porcine collagen-derived matrix to stimulate healing of diabetic foot wounds in humans.
A novel injectable scaffolding matrix (E-Matrix) has been developed to accelerate wound healing in diabetic foot ulcers. This porcine collagen-derived matrix is designed to mimic tertiary embryonic connective tissue and to stimulate fetal wound repair mechanisms including angiogenesis. In vitro and animal studies have indicated a beneficial effect on tissue growth and an acceptable safety profile. In this report, we describe the initial use of this product in a pilot study of six humans with chronic nonhealing diabetic foot ulcers. A dramatic initial response to injection was seen, with an average wound size reduction of 72% 2 weeks after injection. Randomized trials are underway to define the potential benefit of this new treatment modality for diabetic foot ulcers.
Marston
William A
WA
Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, 27599-7212, USA. sky@med.unc.edu
Usala
Anton
A
Hill
Ronald S
RS
Mendes
Robert
R
Minsley
Mary-Ann
MA
D000368:Aged; D001688:Biological Products / Q000008:administration & dosage*; D003094:Collagen / Q000008:administration & dosage*; D003911:Dextrans / Q000008:administration & dosage*; D017719:Diabetic Foot / Q000188:drug therapy*; D004338:Drug Combinations; D005240:Feasibility Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D014945:Wound Healing / Q000187:drug effects*
D001688:Biological Products; D003911:Dextrans; D004338:Drug Combinations; D003094:Collagen